AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Clinuvel is an international pharmaceutical firm which is focused on developing and marketing treatments for a range of disorders
- Since FY2017, the company has been revenue and cashflow positive
- In the coming five years, the company intends to make all divisions profitable
Clinuvel Pharmaceuticals Limited (ASX:CUV) is an international pharmaceutical company which is engaged in the development and commercialization of treatments for patients with acute, genetic, systematic, metabolic and life-threatening disorders. Also, the company offers healthcare solutions to the public.
In the financial year 2023, the company reported a 23.92% YoY growth in total revenue to AUD83.01 million, a 32.80% YoY rise in net profit before income tax to AUD 45.57 million and a 29% YoY jump in cash reserves to AUD 156.8 million. The demand for its lead therapy – SCENESSE- drove the yearly revenue.
Since FY17, the company has continuously delivered positive profits and cash flows.
Top 10 shareholders of CUV
The top 10 shareholders of CUV have around 27.79% shareholding in the company, while the top four have nearly 19.58% stake. Wolgen (Philippe Jacques) and Ender 1, LLC have the highest shareholding in the company, with a stake of ~6.32% and ~5.24%, respectively.
Recent business update
Through an ASX filing dated 18 October 2023, the company shared that it has commenced the global Phase III vitiligo study with SCENESSE administered as a treatment to the first patient with vitiligo. The study will comprise around 200 adult and adolescent patients with vitiligo and darker skin types.
Outlook
The company is focused on diversifying its activities and fueling its profitability through its multiple divisions. In the coming five years, the company expects to make its four divisions – healthcare solutions, pharmaceuticals, branding & marketing and manufacturing & communications-profitable.
CUV plans to enter into in-licensing contracts and undertake acquisition to add complementary technologies further.
Furthermore, the focus is on developing three PhotoCosmetic product lines to be marketed across the globe.
Share performance of CUV
Shares of CUV closed 0.63% higher at AUD 15.96 apiece on 18 October 2023. With this, CUV’s share price dropped by 40.18% in the last nine months and increased by 0.50% in the last one week.
The 52-week high of CUV is AUD 8.72 apiece, recorded on 30 January 2023, and the 52-week low is AUD 13.97 apiece, recorded on 4 October 2023.
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 18 October 2023. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer
This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.
